Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 8/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13240512 | 0.86 | LMNA (0.58) | LMNAMAPK1HTTALDH1A1MAPT | |
| SCHEMBL11514674 | 0.86 | LMNA (0.58) | LMNAMAPK1HTTALDH1A1MAPT | |
| SCHEMBL97994 | 0.85 | LMNA (0.62) | LMNAMAPK1HTTALDH1A1MAPT | |
| SCHEMBL10830938 | 0.84 | TNF (0.58) | LMNAMAPK1HTTALDH1A1MAPT | |
| SCHEMBL9382406 | 0.83 | POLB (0.57) | LMNAMAPK1HTTALDH1A1MAPT | |
| SCHEMBL30530511 | 0.83 | MAPK1 (0.70) | LMNAMAPK1HTTALDH1A1MAPT | |
| SCHEMBL97551 | 0.83 | MAPK1 (0.70) | LMNAMAPK1HTTALDH1A1MAPT | |
| SCHEMBL11132570 | 0.82 | LMNA (0.56) | LMNAMAPK1HTTALDH1A1MAPT | |
| SCHEMBL30277537 | 0.81 | LMNA (0.69) | LMNAMAPK1HTTALDH1A1MAPT | |
| SCHEMBL318787 | 0.81 | LMNA (0.69) | LMNAMAPK1HTTALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142553-B1 | PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF | INTERVET INT BV (NL) | 2015-08-19 | — | — | EP | claimed |
| US-8362006-B2 | Processes for making zilpaterol and salts thereof | INTERVET INTERNATIONAL B.V. (NL) | 2013-01-29 | — | — | US | claimed |
| EP-2535340-A2 | Process for making zilpaterol and salts thereof | Intervet International B.V. (NL) | 2012-12-19 | — | — | EP | claimed |
| US-20100121050-A1 | PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF | INTERVET INTERNATIONAL B.V. (NL) | 2010-05-13 | — | — | US | claimed |
| EP-2142553-A1 | PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF | Intervet International B.V. (NL) | 2010-01-13 | — | — | EP | claimed |
| WO-2008119754-A1 | PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF | INTERVET INTERNATIONAL B.V. (NL) | 2008-10-09 | — | — | WO | claimed |
| EP-3190114-B1 | PROCESS FOR MAKING A CRYSTALLINE ZILPATEROL SALT | INTERVET INT BV (NL) | 2019-11-06 | — | — | EP | disclosed |
| EP-3190114-A1 | PROCESS FOR MAKING A CRYSTALLINE ZILPATEROL SALT | Intervet International B.V. (NL) | 2017-07-12 | — | — | EP | disclosed |
| EP-2535340-B1 | Process for making zilpaterol and salts thereof | INTERVET INT BV (NL) | 2016-04-27 | — | — | EP | disclosed |
| EP-2142553-B1 | PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF | INTERVET INT BV (NL) | 2015-08-19 | — | — | EP | disclosed |
| US-20130109673-A1 | PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF | DUBUIS STEPHANE (CH) | 2013-05-02 | — | — | US | disclosed |
| US-8362006-B2 | Processes for making zilpaterol and salts thereof | INTERVET INTERNATIONAL B.V. (NL) | 2013-01-29 | — | — | US | disclosed |
| US-8343956-B2 | Process for making a crystalline zilpaterol salt | INTERVET INTERNATIONAL B.V. (NL) | 2013-01-01 | — | — | US | disclosed |
| EP-2535340-A2 | Process for making zilpaterol and salts thereof | Intervet International B.V. (NL) | 2012-12-19 | — | — | EP | disclosed |
| US-20120058189-A1 | PROCESS FOR MAKING A CRYSTALLINE ZILPATEROL SALT | INTERVET INTERNATIONAL B.V. (NL) | 2012-03-08 | — | — | US | disclosed |
| EP-2379560-A1 | PROCESS FOR MAKING A CRYSTALLINE ZILPATEROL SALT | Intervet International BV (NL) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010070004-A1 | PROCESS FOR MAKING A CRYSTALLINE ZILPATEROL SALT | INTERVET INTERNATIONAL B.V. (NL) | 2010-06-24 | — | — | WO | disclosed |
| US-20100121050-A1 | PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF | INTERVET INTERNATIONAL B.V. (NL) | 2010-05-13 | — | — | US | disclosed |
| EP-2142553-A1 | PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF | Intervet International B.V. (NL) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119754-A1 | PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF | INTERVET INTERNATIONAL B.V. (NL) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121050-A1 | PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF | SLC39A11, SLC39A3, ZFR | LMNA 1307/4885MAPK1 2812/4885HTT 2296/4885 |
| US-20120058189-A1 | PROCESS FOR MAKING A CRYSTALLINE ZILPATEROL SALT | ZFX, SLC39A11, ZNF277 | LMNA 1285/4885MAPK1 1599/4885HTT 1413/4885 |
| US-20130109673-A1 | PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF | SLC39A3, SLC39A11, CPT1A | LMNA 1177/4885MAPK1 2905/4885HTT 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.